Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00244972 · ClinicalTrials.gov registry record · Phase 1
Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
NCT00244972: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00244972 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 74 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (23% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00244972, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of tipifarnib when given together with sorafenib tosylate in treating patients with biopsiable cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Tipifarnib and sorafenib tosylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer.
Primary Outcome
Descriptive statistics and graphical analysis will be used to summarize the data. Categorical variables will be summarized in frequency tables.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Tipifarnib
- DRUG Sorafenib Tosylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2005-10 |
| Est. Completion | 2017-03 |
| Phase | Phase 1 |
What the finished NCT00244972 record still lists
NCT00244972 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 74 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (23% higher).
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00244972 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00244972 about?
NCT00244972 is a clinical study titled "Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer". This phase I trial studies the side effects and best dose of tipifarnib when given together with sorafenib tosylate in treating patients with biopsiable cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Tipifarnib and sorafenib tosylate may ...
What is the current status of trial NCT00244972?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2005-10. Estimated completion is 2017-03.
What interventions are being tested in trial NCT00244972?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Tipifarnib (DRUG), Sorafenib Tosylate (DRUG).
Who is sponsoring clinical trial NCT00244972?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00244972's enrollment target sits among peer trials
74 725th of 2000 higher than 1,269 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422731 · 74 participants · Early Phase 1
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
- NCT03804853 · 74 participants · NA
Rehabilitation Following Reverse Total Shoulder Arthroplasty
- NCT04065776 · 74 participants · NA
Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
- NCT04771156 · 74 participants · Phase 4
Ketorolac in Palatoplasty
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia